nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A5—Beclomethasone—psoriasis	0.146	0.248	CbGbCtD
Vardenafil—CYP3A5—Mycophenolate mofetil—psoriasis	0.0582	0.0987	CbGbCtD
Vardenafil—CYP3A4—Calcitriol—psoriasis	0.0508	0.0862	CbGbCtD
Vardenafil—CYP3A5—Hydrocortisone—psoriasis	0.0467	0.0792	CbGbCtD
Vardenafil—CYP3A5—Cyclosporine—psoriasis	0.0441	0.0748	CbGbCtD
Vardenafil—CYP3A4—Methoxsalen—psoriasis	0.0395	0.067	CbGbCtD
Vardenafil—CYP3A5—Dexamethasone—psoriasis	0.029	0.0492	CbGbCtD
Vardenafil—CYP3A4—Cholecalciferol—psoriasis	0.0262	0.0444	CbGbCtD
Vardenafil—CYP3A4—Triamcinolone—psoriasis	0.0227	0.0385	CbGbCtD
Vardenafil—CYP3A4—Mycophenolate mofetil—psoriasis	0.0227	0.0385	CbGbCtD
Vardenafil—CYP3A4—Betamethasone—psoriasis	0.0195	0.033	CbGbCtD
Vardenafil—CYP3A4—Prednisolone—psoriasis	0.0192	0.0326	CbGbCtD
Vardenafil—CYP3A4—Hydrocortisone—psoriasis	0.0182	0.0309	CbGbCtD
Vardenafil—CYP3A4—Prednisone—psoriasis	0.0181	0.0308	CbGbCtD
Vardenafil—CYP3A4—Cyclosporine—psoriasis	0.0172	0.0292	CbGbCtD
Vardenafil—CYP3A4—Dexamethasone—psoriasis	0.0113	0.0192	CbGbCtD
Vardenafil—PDE11A—Nitric oxide stimulates guanylate cyclase—NOS2—psoriasis	0.00142	0.0477	CbGpPWpGaD
Vardenafil—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00136	0.0457	CbGpPWpGaD
Vardenafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS2—psoriasis	0.00127	0.0425	CbGpPWpGaD
Vardenafil—PDE10A—Nitric oxide stimulates guanylate cyclase—NOS2—psoriasis	0.00127	0.0425	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—SERPINB8—psoriasis	0.00104	0.035	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—SERPINB8—psoriasis	0.000929	0.0312	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—SERPINB8—psoriasis	0.000929	0.0312	CbGpPWpGaD
Vardenafil—PDE1B—Nitric oxide stimulates guanylate cyclase—NOS2—psoriasis	0.000643	0.0216	CbGpPWpGaD
Vardenafil—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000633	0.0212	CbGpPWpGaD
Vardenafil—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000565	0.019	CbGpPWpGaD
Vardenafil—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000558	0.0187	CbGpPWpGaD
Vardenafil—PDE11A—Platelet homeostasis—NOS2—psoriasis	0.000554	0.0186	CbGpPWpGaD
Vardenafil—PDE5A—Platelet homeostasis—NOS2—psoriasis	0.000494	0.0166	CbGpPWpGaD
Vardenafil—PDE10A—Platelet homeostasis—NOS2—psoriasis	0.000494	0.0166	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—SERPINB8—psoriasis	0.000471	0.0158	CbGpPWpGaD
Vardenafil—PDE6G—Diseases associated with visual transduction—APOE—psoriasis	0.000464	0.0156	CbGpPWpGaD
Vardenafil—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000458	0.0154	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—HCAR2—psoriasis	0.000399	0.0134	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—HCAR2—psoriasis	0.000362	0.0122	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—HCAR2—psoriasis	0.000356	0.0119	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—HCAR2—psoriasis	0.000323	0.0108	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—ITGAL—psoriasis	0.000303	0.0102	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—HLA-C—psoriasis	0.000273	0.00915	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—ITGAL—psoriasis	0.00027	0.00905	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—ITGAL—psoriasis	0.00027	0.00905	CbGpPWpGaD
Vardenafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000263	0.00882	CbGpPWpGaD
Vardenafil—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000259	0.0087	CbGpPWpGaD
Vardenafil—PDE1B—Platelet homeostasis—NOS2—psoriasis	0.00025	0.0084	CbGpPWpGaD
Vardenafil—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000243	0.00817	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—HLA-E—psoriasis	0.00024	0.00807	CbGpPWpGaD
Vardenafil—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.00024	0.00806	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—HLA-E—psoriasis	0.000226	0.00759	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HCAR2—psoriasis	0.000214	0.00718	CbGpPWpGaD
Vardenafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000213	0.00715	CbGpPWpGaD
Vardenafil—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00021	0.00705	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KIR2DS1—psoriasis	0.00021	0.00704	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—CCL20—psoriasis	0.000207	0.00695	CbGpPWpGaD
Vardenafil—Diarrhoea—Mycophenolic acid—psoriasis	0.000203	0.000532	CcSEcCtD
Vardenafil—Angiopathy—Prednisone—psoriasis	0.000202	0.000531	CcSEcCtD
Vardenafil—Conjunctivitis—Methotrexate—psoriasis	0.000202	0.00053	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000202	0.00053	CcSEcCtD
Vardenafil—Immune system disorder—Prednisone—psoriasis	0.000201	0.000529	CcSEcCtD
Vardenafil—Malaise—Dexamethasone—psoriasis	0.000201	0.000528	CcSEcCtD
Vardenafil—Malaise—Betamethasone—psoriasis	0.000201	0.000528	CcSEcCtD
Vardenafil—Anaphylactic shock—Triamcinolone—psoriasis	0.0002	0.000527	CcSEcCtD
Vardenafil—Vertigo—Dexamethasone—psoriasis	0.0002	0.000526	CcSEcCtD
Vardenafil—Vertigo—Betamethasone—psoriasis	0.0002	0.000526	CcSEcCtD
Vardenafil—Syncope—Dexamethasone—psoriasis	0.0002	0.000525	CcSEcCtD
Vardenafil—Syncope—Betamethasone—psoriasis	0.0002	0.000525	CcSEcCtD
Vardenafil—Pain—Mycophenolate mofetil—psoriasis	0.0002	0.000525	CcSEcCtD
Vardenafil—Infection—Triamcinolone—psoriasis	0.000199	0.000523	CcSEcCtD
Vardenafil—Sweating—Methotrexate—psoriasis	0.000199	0.000523	CcSEcCtD
Vardenafil—Hypotension—Hydrocortisone—psoriasis	0.000199	0.000523	CcSEcCtD
Vardenafil—Haematuria—Methotrexate—psoriasis	0.000198	0.00052	CcSEcCtD
Vardenafil—Feeling abnormal—Cyclosporine—psoriasis	0.000197	0.000519	CcSEcCtD
Vardenafil—Shock—Triamcinolone—psoriasis	0.000197	0.000518	CcSEcCtD
Vardenafil—Insomnia—Prednisolone—psoriasis	0.000197	0.000518	CcSEcCtD
Vardenafil—Hepatobiliary disease—Methotrexate—psoriasis	0.000196	0.000516	CcSEcCtD
Vardenafil—Gastrointestinal pain—Cyclosporine—psoriasis	0.000196	0.000515	CcSEcCtD
Vardenafil—Loss of consciousness—Betamethasone—psoriasis	0.000196	0.000515	CcSEcCtD
Vardenafil—Loss of consciousness—Dexamethasone—psoriasis	0.000196	0.000515	CcSEcCtD
Vardenafil—Dizziness—Mycophenolic acid—psoriasis	0.000196	0.000514	CcSEcCtD
Vardenafil—Epistaxis—Methotrexate—psoriasis	0.000196	0.000514	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—HCAR2—psoriasis	0.000196	0.00657	CbGpPWpGaD
Vardenafil—Paraesthesia—Prednisolone—psoriasis	0.000196	0.000514	CcSEcCtD
Vardenafil—Tachycardia—Triamcinolone—psoriasis	0.000196	0.000514	CcSEcCtD
Vardenafil—Mental disorder—Prednisone—psoriasis	0.000195	0.000513	CcSEcCtD
Vardenafil—Erythema—Prednisone—psoriasis	0.000194	0.00051	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000194	0.00051	CcSEcCtD
Vardenafil—Hyperhidrosis—Triamcinolone—psoriasis	0.000194	0.000509	CcSEcCtD
Vardenafil—Convulsion—Dexamethasone—psoriasis	0.000193	0.000507	CcSEcCtD
Vardenafil—Convulsion—Betamethasone—psoriasis	0.000193	0.000507	CcSEcCtD
Vardenafil—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000193	0.000506	CcSEcCtD
Vardenafil—Insomnia—Hydrocortisone—psoriasis	0.000193	0.000506	CcSEcCtD
Vardenafil—Paraesthesia—Hydrocortisone—psoriasis	0.000191	0.000502	CcSEcCtD
Vardenafil—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000191	0.000502	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—HCAR2—psoriasis	0.000191	0.0064	CbGpPWpGaD
Vardenafil—Myalgia—Betamethasone—psoriasis	0.00019	0.000498	CcSEcCtD
Vardenafil—Myalgia—Dexamethasone—psoriasis	0.00019	0.000498	CcSEcCtD
Vardenafil—Abdominal pain—Cyclosporine—psoriasis	0.000189	0.000497	CcSEcCtD
Vardenafil—Anxiety—Betamethasone—psoriasis	0.000189	0.000497	CcSEcCtD
Vardenafil—Anxiety—Dexamethasone—psoriasis	0.000189	0.000497	CcSEcCtD
Vardenafil—Vomiting—Mycophenolic acid—psoriasis	0.000188	0.000495	CcSEcCtD
Vardenafil—PDE11A—Signaling by GPCR—CCL20—psoriasis	0.000188	0.00631	CbGpPWpGaD
Vardenafil—Discomfort—Dexamethasone—psoriasis	0.000187	0.000492	CcSEcCtD
Vardenafil—Discomfort—Betamethasone—psoriasis	0.000187	0.000492	CcSEcCtD
Vardenafil—Dyspepsia—Hydrocortisone—psoriasis	0.000187	0.000492	CcSEcCtD
Vardenafil—Haemoglobin—Methotrexate—psoriasis	0.000187	0.000492	CcSEcCtD
Vardenafil—Rash—Mycophenolic acid—psoriasis	0.000187	0.00049	CcSEcCtD
Vardenafil—Dermatitis—Mycophenolic acid—psoriasis	0.000186	0.00049	CcSEcCtD
Vardenafil—Pain—Prednisolone—psoriasis	0.000186	0.00049	CcSEcCtD
Vardenafil—Haemorrhage—Methotrexate—psoriasis	0.000186	0.00049	CcSEcCtD
Vardenafil—PDE11A—Signaling Pathways—TAGAP—psoriasis	0.000186	0.00623	CbGpPWpGaD
Vardenafil—Headache—Mycophenolic acid—psoriasis	0.000185	0.000487	CcSEcCtD
Vardenafil—Pharyngitis—Methotrexate—psoriasis	0.000185	0.000486	CcSEcCtD
Vardenafil—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000185	0.000485	CcSEcCtD
Vardenafil—PDE10A—GPCR downstream signaling—CCL20—psoriasis	0.000185	0.0062	CbGpPWpGaD
Vardenafil—Urinary tract disorder—Methotrexate—psoriasis	0.000184	0.000483	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000184	0.000483	CcSEcCtD
Vardenafil—Vision blurred—Prednisone—psoriasis	0.000183	0.000481	CcSEcCtD
Vardenafil—Urethral disorder—Methotrexate—psoriasis	0.000183	0.00048	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000183	0.00048	CcSEcCtD
Vardenafil—Pain—Hydrocortisone—psoriasis	0.000182	0.000478	CcSEcCtD
Vardenafil—Anaphylactic shock—Betamethasone—psoriasis	0.000182	0.000478	CcSEcCtD
Vardenafil—Anaphylactic shock—Dexamethasone—psoriasis	0.000182	0.000478	CcSEcCtD
Vardenafil—Insomnia—Triamcinolone—psoriasis	0.000181	0.000476	CcSEcCtD
Vardenafil—Infection—Dexamethasone—psoriasis	0.000181	0.000475	CcSEcCtD
Vardenafil—Infection—Betamethasone—psoriasis	0.000181	0.000475	CcSEcCtD
Vardenafil—PDE1B—GPCR downstream signaling—HCAR2—psoriasis	0.00018	0.00605	CbGpPWpGaD
Vardenafil—Ill-defined disorder—Prednisone—psoriasis	0.00018	0.000473	CcSEcCtD
Vardenafil—Paraesthesia—Triamcinolone—psoriasis	0.00018	0.000473	CcSEcCtD
Vardenafil—Feeling abnormal—Prednisolone—psoriasis	0.00018	0.000472	CcSEcCtD
Vardenafil—Visual impairment—Methotrexate—psoriasis	0.00018	0.000472	CcSEcCtD
Vardenafil—Shock—Dexamethasone—psoriasis	0.000179	0.00047	CcSEcCtD
Vardenafil—Shock—Betamethasone—psoriasis	0.000179	0.00047	CcSEcCtD
Vardenafil—Dyspnoea—Triamcinolone—psoriasis	0.000179	0.00047	CcSEcCtD
Vardenafil—Nervous system disorder—Betamethasone—psoriasis	0.000178	0.000469	CcSEcCtD
Vardenafil—Nervous system disorder—Dexamethasone—psoriasis	0.000178	0.000469	CcSEcCtD
Vardenafil—Tachycardia—Betamethasone—psoriasis	0.000177	0.000466	CcSEcCtD
Vardenafil—Tachycardia—Dexamethasone—psoriasis	0.000177	0.000466	CcSEcCtD
Vardenafil—Angioedema—Prednisone—psoriasis	0.000177	0.000466	CcSEcCtD
Vardenafil—Hypersensitivity—Cyclosporine—psoriasis	0.000176	0.000464	CcSEcCtD
Vardenafil—Dyspepsia—Triamcinolone—psoriasis	0.000176	0.000464	CcSEcCtD
Vardenafil—Nausea—Mycophenolic acid—psoriasis	0.000176	0.000462	CcSEcCtD
Vardenafil—Hyperhidrosis—Betamethasone—psoriasis	0.000176	0.000462	CcSEcCtD
Vardenafil—Hyperhidrosis—Dexamethasone—psoriasis	0.000176	0.000462	CcSEcCtD
Vardenafil—Feeling abnormal—Hydrocortisone—psoriasis	0.000175	0.000461	CcSEcCtD
Vardenafil—Malaise—Prednisone—psoriasis	0.000175	0.00046	CcSEcCtD
Vardenafil—Vertigo—Prednisone—psoriasis	0.000174	0.000458	CcSEcCtD
Vardenafil—Eye disorder—Methotrexate—psoriasis	0.000174	0.000457	CcSEcCtD
Vardenafil—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000174	0.000457	CcSEcCtD
Vardenafil—Syncope—Prednisone—psoriasis	0.000174	0.000457	CcSEcCtD
Vardenafil—Tinnitus—Methotrexate—psoriasis	0.000174	0.000456	CcSEcCtD
Vardenafil—Cardiac disorder—Methotrexate—psoriasis	0.000173	0.000454	CcSEcCtD
Vardenafil—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000172	0.000452	CcSEcCtD
Vardenafil—Asthenia—Cyclosporine—psoriasis	0.000172	0.000452	CcSEcCtD
Vardenafil—Pain—Triamcinolone—psoriasis	0.000171	0.00045	CcSEcCtD
Vardenafil—Loss of consciousness—Prednisone—psoriasis	0.000171	0.000448	CcSEcCtD
Vardenafil—Hypotension—Dexamethasone—psoriasis	0.00017	0.000447	CcSEcCtD
Vardenafil—Hypotension—Betamethasone—psoriasis	0.00017	0.000447	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—TAGAP—psoriasis	0.00017	0.00569	CbGpPWpGaD
Vardenafil—Pruritus—Cyclosporine—psoriasis	0.000169	0.000445	CcSEcCtD
Vardenafil—Angiopathy—Methotrexate—psoriasis	0.000169	0.000444	CcSEcCtD
Vardenafil—Immune system disorder—Methotrexate—psoriasis	0.000168	0.000442	CcSEcCtD
Vardenafil—Abdominal pain—Hydrocortisone—psoriasis	0.000168	0.000442	CcSEcCtD
Vardenafil—Convulsion—Prednisone—psoriasis	0.000168	0.000442	CcSEcCtD
Vardenafil—Mediastinal disorder—Methotrexate—psoriasis	0.000168	0.000441	CcSEcCtD
Vardenafil—PDE10A—Signaling by GPCR—CCL20—psoriasis	0.000168	0.00563	CbGpPWpGaD
Vardenafil—Asthenia—Mycophenolate mofetil—psoriasis	0.000168	0.00044	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000166	0.000435	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000166	0.000435	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—TAGAP—psoriasis	0.000165	0.00555	CbGpPWpGaD
Vardenafil—Pruritus—Mycophenolate mofetil—psoriasis	0.000165	0.000434	CcSEcCtD
Vardenafil—Arthralgia—Prednisone—psoriasis	0.000165	0.000434	CcSEcCtD
Vardenafil—Myalgia—Prednisone—psoriasis	0.000165	0.000434	CcSEcCtD
Vardenafil—Feeling abnormal—Triamcinolone—psoriasis	0.000165	0.000434	CcSEcCtD
Vardenafil—Anxiety—Prednisone—psoriasis	0.000165	0.000433	CcSEcCtD
Vardenafil—Insomnia—Dexamethasone—psoriasis	0.000164	0.000432	CcSEcCtD
Vardenafil—Insomnia—Betamethasone—psoriasis	0.000164	0.000432	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000164	0.000431	CcSEcCtD
Vardenafil—Diarrhoea—Cyclosporine—psoriasis	0.000164	0.000431	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—HCAR2—psoriasis	0.000164	0.00549	CbGpPWpGaD
Vardenafil—Paraesthesia—Dexamethasone—psoriasis	0.000163	0.000429	CcSEcCtD
Vardenafil—Paraesthesia—Betamethasone—psoriasis	0.000163	0.000429	CcSEcCtD
Vardenafil—Discomfort—Prednisone—psoriasis	0.000163	0.000429	CcSEcCtD
Vardenafil—Mental disorder—Methotrexate—psoriasis	0.000163	0.000429	CcSEcCtD
Vardenafil—PDE1B—Innate Immune System—DDX58—psoriasis	0.000162	0.00545	CbGpPWpGaD
Vardenafil—Erythema—Methotrexate—psoriasis	0.000162	0.000426	CcSEcCtD
Vardenafil—PDE1B—DAP12 interactions—HLA-B—psoriasis	0.000161	0.00541	CbGpPWpGaD
Vardenafil—Hypersensitivity—Prednisolone—psoriasis	0.000161	0.000422	CcSEcCtD
Vardenafil—Dyspepsia—Dexamethasone—psoriasis	0.00016	0.000421	CcSEcCtD
Vardenafil—Dyspepsia—Betamethasone—psoriasis	0.00016	0.000421	CcSEcCtD
Vardenafil—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00016	0.00042	CcSEcCtD
Vardenafil—Dizziness—Cyclosporine—psoriasis	0.000158	0.000416	CcSEcCtD
Vardenafil—Anaphylactic shock—Prednisone—psoriasis	0.000158	0.000416	CcSEcCtD
Vardenafil—Infection—Prednisone—psoriasis	0.000157	0.000413	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Betamethasone—psoriasis	0.000157	0.000413	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000157	0.000413	CcSEcCtD
Vardenafil—Back pain—Methotrexate—psoriasis	0.000157	0.000412	CcSEcCtD
Vardenafil—Hypersensitivity—Hydrocortisone—psoriasis	0.000157	0.000412	CcSEcCtD
Vardenafil—Shock—Prednisone—psoriasis	0.000156	0.000409	CcSEcCtD
Vardenafil—Pain—Betamethasone—psoriasis	0.000156	0.000409	CcSEcCtD
Vardenafil—Pain—Dexamethasone—psoriasis	0.000156	0.000409	CcSEcCtD
Vardenafil—Nervous system disorder—Prednisone—psoriasis	0.000155	0.000408	CcSEcCtD
Vardenafil—Tachycardia—Prednisone—psoriasis	0.000155	0.000406	CcSEcCtD
Vardenafil—Dizziness—Mycophenolate mofetil—psoriasis	0.000155	0.000406	CcSEcCtD
Vardenafil—Skin disorder—Prednisone—psoriasis	0.000154	0.000404	CcSEcCtD
Vardenafil—Hyperhidrosis—Prednisone—psoriasis	0.000153	0.000402	CcSEcCtD
Vardenafil—Vision blurred—Methotrexate—psoriasis	0.000153	0.000402	CcSEcCtD
Vardenafil—Asthenia—Hydrocortisone—psoriasis	0.000153	0.000401	CcSEcCtD
Vardenafil—Vomiting—Cyclosporine—psoriasis	0.000152	0.0004	CcSEcCtD
Vardenafil—Rash—Cyclosporine—psoriasis	0.000151	0.000397	CcSEcCtD
Vardenafil—Dermatitis—Cyclosporine—psoriasis	0.000151	0.000396	CcSEcCtD
Vardenafil—Pruritus—Hydrocortisone—psoriasis	0.000151	0.000396	CcSEcCtD
Vardenafil—Ill-defined disorder—Methotrexate—psoriasis	0.00015	0.000395	CcSEcCtD
Vardenafil—Headache—Cyclosporine—psoriasis	0.00015	0.000394	CcSEcCtD
Vardenafil—Feeling abnormal—Dexamethasone—psoriasis	0.00015	0.000394	CcSEcCtD
Vardenafil—Feeling abnormal—Betamethasone—psoriasis	0.00015	0.000394	CcSEcCtD
Vardenafil—Gastrointestinal pain—Betamethasone—psoriasis	0.000149	0.000391	CcSEcCtD
Vardenafil—Gastrointestinal pain—Dexamethasone—psoriasis	0.000149	0.000391	CcSEcCtD
Vardenafil—Vomiting—Mycophenolate mofetil—psoriasis	0.000149	0.00039	CcSEcCtD
Vardenafil—Hypersensitivity—Triamcinolone—psoriasis	0.000148	0.000388	CcSEcCtD
Vardenafil—Rash—Mycophenolate mofetil—psoriasis	0.000147	0.000387	CcSEcCtD
Vardenafil—Dermatitis—Mycophenolate mofetil—psoriasis	0.000147	0.000387	CcSEcCtD
Vardenafil—Headache—Mycophenolate mofetil—psoriasis	0.000146	0.000385	CcSEcCtD
Vardenafil—Malaise—Methotrexate—psoriasis	0.000146	0.000384	CcSEcCtD
Vardenafil—Vertigo—Methotrexate—psoriasis	0.000146	0.000383	CcSEcCtD
Vardenafil—Diarrhoea—Hydrocortisone—psoriasis	0.000146	0.000383	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Prednisone—psoriasis	0.000144	0.000379	CcSEcCtD
Vardenafil—Dizziness—Prednisolone—psoriasis	0.000144	0.000379	CcSEcCtD
Vardenafil—Asthenia—Triamcinolone—psoriasis	0.000144	0.000378	CcSEcCtD
Vardenafil—Abdominal pain—Betamethasone—psoriasis	0.000144	0.000378	CcSEcCtD
Vardenafil—Abdominal pain—Dexamethasone—psoriasis	0.000144	0.000378	CcSEcCtD
Vardenafil—Insomnia—Prednisone—psoriasis	0.000143	0.000376	CcSEcCtD
Vardenafil—Nausea—Cyclosporine—psoriasis	0.000142	0.000374	CcSEcCtD
Vardenafil—Paraesthesia—Prednisone—psoriasis	0.000142	0.000374	CcSEcCtD
Vardenafil—Pruritus—Triamcinolone—psoriasis	0.000142	0.000373	CcSEcCtD
Vardenafil—Dizziness—Hydrocortisone—psoriasis	0.000141	0.00037	CcSEcCtD
Vardenafil—Convulsion—Methotrexate—psoriasis	0.000141	0.000369	CcSEcCtD
Vardenafil—Dyspepsia—Prednisone—psoriasis	0.000139	0.000366	CcSEcCtD
Vardenafil—Nausea—Mycophenolate mofetil—psoriasis	0.000139	0.000365	CcSEcCtD
Vardenafil—Chest pain—Methotrexate—psoriasis	0.000138	0.000363	CcSEcCtD
Vardenafil—Arthralgia—Methotrexate—psoriasis	0.000138	0.000363	CcSEcCtD
Vardenafil—Myalgia—Methotrexate—psoriasis	0.000138	0.000363	CcSEcCtD
Vardenafil—Rash—Prednisolone—psoriasis	0.000137	0.000361	CcSEcCtD
Vardenafil—Dermatitis—Prednisolone—psoriasis	0.000137	0.000361	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000137	0.00036	CcSEcCtD
Vardenafil—PDE1B—Hemostasis—ITGAL—psoriasis	0.000137	0.00459	CbGpPWpGaD
Vardenafil—Headache—Prednisolone—psoriasis	0.000137	0.000359	CcSEcCtD
Vardenafil—Discomfort—Methotrexate—psoriasis	0.000136	0.000358	CcSEcCtD
Vardenafil—Vomiting—Hydrocortisone—psoriasis	0.000135	0.000356	CcSEcCtD
Vardenafil—Rash—Hydrocortisone—psoriasis	0.000134	0.000353	CcSEcCtD
Vardenafil—Dermatitis—Hydrocortisone—psoriasis	0.000134	0.000352	CcSEcCtD
Vardenafil—Headache—Hydrocortisone—psoriasis	0.000133	0.00035	CcSEcCtD
Vardenafil—Dizziness—Triamcinolone—psoriasis	0.000133	0.000348	CcSEcCtD
Vardenafil—Anaphylactic shock—Methotrexate—psoriasis	0.000132	0.000348	CcSEcCtD
Vardenafil—Infection—Methotrexate—psoriasis	0.000131	0.000346	CcSEcCtD
Vardenafil—Feeling abnormal—Prednisone—psoriasis	0.000131	0.000343	CcSEcCtD
Vardenafil—Asthenia—Betamethasone—psoriasis	0.00013	0.000343	CcSEcCtD
Vardenafil—Asthenia—Dexamethasone—psoriasis	0.00013	0.000343	CcSEcCtD
Vardenafil—Nervous system disorder—Methotrexate—psoriasis	0.00013	0.000341	CcSEcCtD
Vardenafil—Gastrointestinal pain—Prednisone—psoriasis	0.00013	0.00034	CcSEcCtD
Vardenafil—Nausea—Prednisolone—psoriasis	0.000129	0.00034	CcSEcCtD
Vardenafil—Pruritus—Betamethasone—psoriasis	0.000129	0.000338	CcSEcCtD
Vardenafil—Pruritus—Dexamethasone—psoriasis	0.000129	0.000338	CcSEcCtD
Vardenafil—Skin disorder—Methotrexate—psoriasis	0.000129	0.000338	CcSEcCtD
Vardenafil—Hyperhidrosis—Methotrexate—psoriasis	0.000128	0.000336	CcSEcCtD
Vardenafil—Vomiting—Triamcinolone—psoriasis	0.000127	0.000335	CcSEcCtD
Vardenafil—Nausea—Hydrocortisone—psoriasis	0.000126	0.000332	CcSEcCtD
Vardenafil—Rash—Triamcinolone—psoriasis	0.000126	0.000332	CcSEcCtD
Vardenafil—Dermatitis—Triamcinolone—psoriasis	0.000126	0.000332	CcSEcCtD
Vardenafil—Headache—Triamcinolone—psoriasis	0.000126	0.00033	CcSEcCtD
Vardenafil—Abdominal pain—Prednisone—psoriasis	0.000125	0.000329	CcSEcCtD
Vardenafil—Diarrhoea—Dexamethasone—psoriasis	0.000124	0.000327	CcSEcCtD
Vardenafil—Diarrhoea—Betamethasone—psoriasis	0.000124	0.000327	CcSEcCtD
Vardenafil—PDE11A—Hemostasis—NOS2—psoriasis	0.000124	0.00417	CbGpPWpGaD
Vardenafil—Hypotension—Methotrexate—psoriasis	0.000124	0.000325	CcSEcCtD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—TYK2—psoriasis	0.000122	0.0041	CbGpPWpGaD
Vardenafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000121	0.00405	CbGpPWpGaD
Vardenafil—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000121	0.000317	CcSEcCtD
Vardenafil—Dizziness—Betamethasone—psoriasis	0.00012	0.000316	CcSEcCtD
Vardenafil—Dizziness—Dexamethasone—psoriasis	0.00012	0.000316	CcSEcCtD
Vardenafil—Insomnia—Methotrexate—psoriasis	0.00012	0.000315	CcSEcCtD
Vardenafil—Nausea—Triamcinolone—psoriasis	0.000119	0.000313	CcSEcCtD
Vardenafil—Paraesthesia—Methotrexate—psoriasis	0.000119	0.000312	CcSEcCtD
Vardenafil—Dyspnoea—Methotrexate—psoriasis	0.000118	0.00031	CcSEcCtD
Vardenafil—Somnolence—Methotrexate—psoriasis	0.000118	0.000309	CcSEcCtD
Vardenafil—Hypersensitivity—Prednisone—psoriasis	0.000117	0.000307	CcSEcCtD
Vardenafil—Dyspepsia—Methotrexate—psoriasis	0.000117	0.000306	CcSEcCtD
Vardenafil—Vomiting—Betamethasone—psoriasis	0.000116	0.000304	CcSEcCtD
Vardenafil—Vomiting—Dexamethasone—psoriasis	0.000116	0.000304	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—TYK2—psoriasis	0.000115	0.00385	CbGpPWpGaD
Vardenafil—Rash—Dexamethasone—psoriasis	0.000115	0.000301	CcSEcCtD
Vardenafil—Rash—Betamethasone—psoriasis	0.000115	0.000301	CcSEcCtD
Vardenafil—Dermatitis—Betamethasone—psoriasis	0.000115	0.000301	CcSEcCtD
Vardenafil—Dermatitis—Dexamethasone—psoriasis	0.000115	0.000301	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Methotrexate—psoriasis	0.000114	0.0003	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR—TYK2—psoriasis	0.000114	0.00383	CbGpPWpGaD
Vardenafil—Headache—Dexamethasone—psoriasis	0.000114	0.000299	CcSEcCtD
Vardenafil—Headache—Betamethasone—psoriasis	0.000114	0.000299	CcSEcCtD
Vardenafil—PDE1B—Signaling by ERBB2—TYK2—psoriasis	0.000114	0.00381	CbGpPWpGaD
Vardenafil—Asthenia—Prednisone—psoriasis	0.000114	0.000299	CcSEcCtD
Vardenafil—Pain—Methotrexate—psoriasis	0.000113	0.000297	CcSEcCtD
Vardenafil—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000113	0.0038	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—TYK2—psoriasis	0.000113	0.0038	CbGpPWpGaD
Vardenafil—Pruritus—Prednisone—psoriasis	0.000112	0.000294	CcSEcCtD
Vardenafil—PDE1B—Innate Immune System—IFIH1—psoriasis	0.000112	0.00375	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000112	0.00374	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CCL20—psoriasis	0.000111	0.00373	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—NOS2—psoriasis	0.000111	0.00371	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—NOS2—psoriasis	0.000111	0.00371	CbGpPWpGaD
Vardenafil—Feeling abnormal—Methotrexate—psoriasis	0.000109	0.000287	CcSEcCtD
Vardenafil—Diarrhoea—Prednisone—psoriasis	0.000108	0.000285	CcSEcCtD
Vardenafil—Gastrointestinal pain—Methotrexate—psoriasis	0.000108	0.000284	CcSEcCtD
Vardenafil—Nausea—Betamethasone—psoriasis	0.000108	0.000284	CcSEcCtD
Vardenafil—Nausea—Dexamethasone—psoriasis	0.000108	0.000284	CcSEcCtD
Vardenafil—PDE1B—Immune System—ERAP1—psoriasis	0.000107	0.0036	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—TYK2—psoriasis	0.000106	0.00357	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—TYK2—psoriasis	0.000106	0.00357	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HLA-C—psoriasis	0.000106	0.00355	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—TYK2—psoriasis	0.000105	0.00354	CbGpPWpGaD
Vardenafil—Dizziness—Prednisone—psoriasis	0.000105	0.000275	CcSEcCtD
Vardenafil—Abdominal pain—Methotrexate—psoriasis	0.000105	0.000275	CcSEcCtD
Vardenafil—PDE1B—Innate Immune System—TNFAIP3—psoriasis	0.000105	0.00351	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—TYK2—psoriasis	0.000105	0.00351	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—TYK2—psoriasis	0.000104	0.00349	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CCL20—psoriasis	0.000102	0.00341	CbGpPWpGaD
Vardenafil—Vomiting—Prednisone—psoriasis	0.000101	0.000265	CcSEcCtD
Vardenafil—Rash—Prednisone—psoriasis	9.99e-05	0.000262	CcSEcCtD
Vardenafil—Dermatitis—Prednisone—psoriasis	9.98e-05	0.000262	CcSEcCtD
Vardenafil—Headache—Prednisone—psoriasis	9.92e-05	0.000261	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—CCL20—psoriasis	9.91e-05	0.00332	CbGpPWpGaD
Vardenafil—CYP3A4—Tryptophan metabolism—CAT—psoriasis	9.76e-05	0.00328	CbGpPWpGaD
Vardenafil—Hypersensitivity—Methotrexate—psoriasis	9.75e-05	0.000256	CcSEcCtD
Vardenafil—PDE1B—Signaling Pathways—HCAR2—psoriasis	9.67e-05	0.00324	CbGpPWpGaD
Vardenafil—Asthenia—Methotrexate—psoriasis	9.5e-05	0.00025	CcSEcCtD
Vardenafil—PDE1B—Immune System—DDX58—psoriasis	9.46e-05	0.00317	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	9.43e-05	0.00316	CbGpPWpGaD
Vardenafil—Nausea—Prednisone—psoriasis	9.41e-05	0.000247	CcSEcCtD
Vardenafil—Pruritus—Methotrexate—psoriasis	9.36e-05	0.000246	CcSEcCtD
Vardenafil—PDE1B—GPCR downstream signaling—CCL20—psoriasis	9.36e-05	0.00314	CbGpPWpGaD
Vardenafil—Diarrhoea—Methotrexate—psoriasis	9.06e-05	0.000238	CcSEcCtD
Vardenafil—PDE1B—Signaling by NGF—NFKBIA—psoriasis	8.85e-05	0.00297	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HLA-E—psoriasis	8.79e-05	0.00295	CbGpPWpGaD
Vardenafil—Dizziness—Methotrexate—psoriasis	8.75e-05	0.00023	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—CCL20—psoriasis	8.5e-05	0.00285	CbGpPWpGaD
Vardenafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.42e-05	0.00282	CbGpPWpGaD
Vardenafil—Vomiting—Methotrexate—psoriasis	8.42e-05	0.000221	CcSEcCtD
Vardenafil—PDE1B—Signaling Pathways—TAGAP—psoriasis	8.38e-05	0.00281	CbGpPWpGaD
Vardenafil—Rash—Methotrexate—psoriasis	8.35e-05	0.000219	CcSEcCtD
Vardenafil—Dermatitis—Methotrexate—psoriasis	8.34e-05	0.000219	CcSEcCtD
Vardenafil—Headache—Methotrexate—psoriasis	8.29e-05	0.000218	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—STAT3—psoriasis	8.04e-05	0.0027	CbGpPWpGaD
Vardenafil—Nausea—Methotrexate—psoriasis	7.86e-05	0.000207	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR in disease—STAT3—psoriasis	7.45e-05	0.0025	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—SOCS1—psoriasis	7.34e-05	0.00246	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—STAT3—psoriasis	7.29e-05	0.00245	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—TYK2—psoriasis	7.25e-05	0.00243	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—VEGFA—psoriasis	7.19e-05	0.00241	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ITGAL—psoriasis	7.17e-05	0.0024	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—REL—psoriasis	6.7e-05	0.00225	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	6.6e-05	0.00221	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IFIH1—psoriasis	6.51e-05	0.00218	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—VEGFA—psoriasis	6.41e-05	0.00215	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—VEGFA—psoriasis	6.41e-05	0.00215	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HLA-A—psoriasis	6.32e-05	0.00212	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HLA-B—psoriasis	6.26e-05	0.0021	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HLA-C—psoriasis	6.17e-05	0.00207	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SOCS1—psoriasis	6.12e-05	0.00205	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—TNFAIP3—psoriasis	6.09e-05	0.00204	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—IL6—psoriasis	5.97e-05	0.002	CbGpPWpGaD
Vardenafil—PDE6G—Disease—APOE—psoriasis	5.9e-05	0.00198	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—TYK2—psoriasis	5.84e-05	0.00196	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—NFKB1—psoriasis	5.65e-05	0.0019	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—IL6—psoriasis	5.62e-05	0.00188	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—NOS2—psoriasis	5.61e-05	0.00188	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SOCS1—psoriasis	5.6e-05	0.00188	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—CXCL8—psoriasis	5.6e-05	0.00188	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—IL6—psoriasis	5.59e-05	0.00187	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—IL6—psoriasis	5.56e-05	0.00187	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CRP—psoriasis	5.54e-05	0.00186	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—IL6—psoriasis	5.53e-05	0.00186	CbGpPWpGaD
Vardenafil—PDE6G—Disease—NOS2—psoriasis	5.5e-05	0.00184	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SOCS1—psoriasis	5.46e-05	0.00183	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—TP53—psoriasis	5.43e-05	0.00182	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—IL6—psoriasis	5.21e-05	0.00175	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—IL6—psoriasis	5.21e-05	0.00175	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—TYK2—psoriasis	5.2e-05	0.00175	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—IL6—psoriasis	5.16e-05	0.00173	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HLA-E—psoriasis	5.12e-05	0.00172	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—IL6—psoriasis	5.11e-05	0.00172	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—IL6—psoriasis	5.09e-05	0.00171	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—CXCL8—psoriasis	5.08e-05	0.0017	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—STAT3—psoriasis	5.08e-05	0.0017	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—NFKBIA—psoriasis	5.05e-05	0.00169	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CCL20—psoriasis	5.02e-05	0.00168	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—CXCL8—psoriasis	4.99e-05	0.00167	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—NDUFA5—psoriasis	4.9e-05	0.00164	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—TP53—psoriasis	4.84e-05	0.00162	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—TP53—psoriasis	4.84e-05	0.00162	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	4.61e-05	0.00155	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—CXCL8—psoriasis	4.53e-05	0.00152	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—LEP—psoriasis	4.52e-05	0.00152	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—APOE—psoriasis	4.52e-05	0.00152	CbGpPWpGaD
Vardenafil—PDE6G—Disease—TYK2—psoriasis	4.5e-05	0.00151	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—SOCS1—psoriasis	4.28e-05	0.00143	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NFKBIA—psoriasis	4.21e-05	0.00141	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CYP2S1—psoriasis	4.16e-05	0.0014	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—TYK2—psoriasis	4.14e-05	0.00139	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—LEP—psoriasis	4.13e-05	0.00139	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—APOE—psoriasis	4.13e-05	0.00139	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CD4—psoriasis	4.07e-05	0.00137	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—APOE—psoriasis	4.03e-05	0.00135	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—LEP—psoriasis	4.03e-05	0.00135	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NFKBIA—psoriasis	3.85e-05	0.00129	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CD8A—psoriasis	3.79e-05	0.00127	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NFKBIA—psoriasis	3.75e-05	0.00126	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CD4—psoriasis	3.74e-05	0.00125	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HLA-B—psoriasis	3.65e-05	0.00122	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—IL6—psoriasis	3.55e-05	0.00119	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TYK2—psoriasis	3.45e-05	0.00116	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HLA-A—psoriasis	3.38e-05	0.00113	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—JUN—psoriasis	3.35e-05	0.00112	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—VEGFA—psoriasis	3.25e-05	0.00109	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CRP—psoriasis	3.22e-05	0.00108	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—NFKB1—psoriasis	3.22e-05	0.00108	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TYK2—psoriasis	3.15e-05	0.00106	CbGpPWpGaD
Vardenafil—PDE6G—Disease—STAT3—psoriasis	3.15e-05	0.00106	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HLA-A—psoriasis	3.12e-05	0.00105	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HLA-DRB1—psoriasis	3.09e-05	0.00104	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TYK2—psoriasis	3.07e-05	0.00103	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CXCL8—psoriasis	3e-05	0.00101	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ICAM1—psoriasis	2.96e-05	0.000994	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NFKBIA—psoriasis	2.94e-05	0.000987	CbGpPWpGaD
Vardenafil—PDE1B—Disease—APOE—psoriasis	2.91e-05	0.000978	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—IL6—psoriasis	2.85e-05	0.000958	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—JUN—psoriasis	2.79e-05	0.000936	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SOCS1—psoriasis	2.76e-05	0.000928	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CXCL8—psoriasis	2.75e-05	0.000921	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NOS2—psoriasis	2.72e-05	0.000911	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NFKB1—psoriasis	2.69e-05	0.000901	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CXCL8—psoriasis	2.68e-05	0.000898	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—TYK2—psoriasis	2.64e-05	0.000884	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—JUN—psoriasis	2.55e-05	0.000856	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—IL6—psoriasis	2.54e-05	0.000854	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—CXCL8—psoriasis	2.53e-05	0.000848	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—JUN—psoriasis	2.49e-05	0.000834	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NFKB1—psoriasis	2.46e-05	0.000824	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—psoriasis	2.45e-05	0.000823	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—VEGFA—psoriasis	2.44e-05	0.000818	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—STAT3—psoriasis	2.41e-05	0.00081	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—TYK2—psoriasis	2.41e-05	0.000808	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NFKB1—psoriasis	2.39e-05	0.000803	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—CXCL8—psoriasis	2.3e-05	0.00077	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NDUFA5—psoriasis	2.28e-05	0.000764	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IFNG—psoriasis	2.26e-05	0.000757	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—VEGFA—psoriasis	2.23e-05	0.000748	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TYK2—psoriasis	2.22e-05	0.000746	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—STAT3—psoriasis	2.21e-05	0.000741	CbGpPWpGaD
Vardenafil—PDE6G—Disease—IL6—psoriasis	2.2e-05	0.000739	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CD4—psoriasis	2.18e-05	0.000731	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—VEGFA—psoriasis	2.17e-05	0.000729	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—STAT3—psoriasis	2.15e-05	0.000722	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—LEP—psoriasis	2.04e-05	0.000685	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—APOE—psoriasis	2.04e-05	0.000685	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CARM1—psoriasis	2.03e-05	0.000682	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—IL6—psoriasis	2.02e-05	0.000679	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CD4—psoriasis	2.01e-05	0.000675	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—JUN—psoriasis	1.95e-05	0.000654	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CYP2S1—psoriasis	1.94e-05	0.000649	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NFKBIA—psoriasis	1.9e-05	0.000638	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NFKB1—psoriasis	1.88e-05	0.00063	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—psoriasis	1.84e-05	0.000618	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—STAT3—psoriasis	1.69e-05	0.000566	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IL6—psoriasis	1.69e-05	0.000566	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—psoriasis	1.68e-05	0.000565	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—psoriasis	1.64e-05	0.000551	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TYK2—psoriasis	1.56e-05	0.000522	CbGpPWpGaD
Vardenafil—PDE1B—Disease—STAT3—psoriasis	1.56e-05	0.000522	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IL6—psoriasis	1.54e-05	0.000517	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IL6—psoriasis	1.5e-05	0.000504	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CXCL8—psoriasis	1.36e-05	0.000455	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—IL6—psoriasis	1.29e-05	0.000433	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—JUN—psoriasis	1.26e-05	0.000423	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CAT—psoriasis	1.25e-05	0.00042	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NFKB1—psoriasis	1.21e-05	0.000407	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IL6—psoriasis	1.18e-05	0.000395	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—VEGFA—psoriasis	1.1e-05	0.000369	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—STAT3—psoriasis	1.09e-05	0.000366	CbGpPWpGaD
Vardenafil—PDE1B—Disease—IL6—psoriasis	1.09e-05	0.000365	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—APOE—psoriasis	9.72e-06	0.000326	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CARM1—psoriasis	9.45e-06	0.000317	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PPARG—psoriasis	8.46e-06	0.000284	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—psoriasis	8.32e-06	0.000279	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IL6—psoriasis	7.62e-06	0.000256	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CAT—psoriasis	5.81e-06	0.000195	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—APOE—psoriasis	4.52e-06	0.000152	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PPARG—psoriasis	3.93e-06	0.000132	CbGpPWpGaD
